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Mutantsofneuroserpinare retainedaspolymerswithin theendoplasmic reticulum(ER)ofneurones tocause the
autosomaldominantdementia familial encephalopathywithneuroserpin inclusionbodiesorFENIB.Thecellular
consequencesareunusual in that theorderedpolymers activate theERoverload response (EOR) in theabsence
of the canonical unfolded protein response. We use both cell lines and Drosophilamodels to show that the
G392Emutantofneuroserpin that formspolymers isdegradedbyUBE2j1E2 ligaseandHrd1E3 ligasewhile trun-
cated neuroserpin, a protein that lacks 132 amino acids, is degraded by UBE2g2 (E2) and gp78 (E3) ligases. The
degradation of G392E neuroserpin results from SREBP-dependent activation of the cholesterol biosynthetic
pathway in cells that express polymers of neuroserpin (G392E). Inhibition of HMGCoA reductase, the limiting
enzyme of the cholesterol biosynthetic pathway, reduced the ubiquitination of G392E neuroserpin in our cell
lines and increased the retention of neuroserpin polymers in both HeLa cells and primary neurones. Our data
reveal a reciprocal relationship between cholesterol biosynthesis and the clearance of mutant neuroserpin.
This represents the first description of a link between sterol metabolism and modulation of the proteotoxicity
mediated by the EOR.
INTRODUCTION
Neuroserpin is a member of the SERPIN super family of serine
protease inhibitors (1). It is mainly synthesized and secreted
from neurones of the central and peripheral nervous systems
(2,3), but it has also been detected in the heart, kidney, spinal
cord and testis (3). Neuroserpin is believed to inhibit tissue-type
plasminogen activator (tPA) (4) and plays an important role in
physiological processes such as synaptic plasticity (2,5) and
memory (6,7) and in the pathogenesis of neurological disorders
mediated by excitotoxicity, such as stroke (2,8–11). Through
interaction with the low-density lipoprotein receptor-related
protein, neuroserpin may also mediate internalization of tPA
complexes to regulate its proteolytic activity (12). Although
mice engineered to lack expression of neuroserpin do not
display altered tPA activity in the brain, they do exhibit altered
emotional responses (13).
Mutations in neuroserpin underlie the autosomal dominant
dementia familial encephalopathy with neuroserpin inclusion
bodies (FENIB) (14–16). This dementia is characterized by eo-
sinophilic neuronal inclusions of neuroserpin (Collins bodies)
within the deeper layers of the cerebral cortex and substantia
nigra. Six mutations of neuroserpin have been identified in
FENIB resulting in a spectrum of symptoms from dementia in
middle age to severe epilepsy under the age of 10 years (17).
The mutations (Ser49Pro, Leu47Pro, Ser52Arg, His338Arg,
Gly392Arg and Gly392Glu) cluster in the shutter domain of neu-
roserpin and result in the formation of ordered polymers within
the endoplasmic reticulum (ER) (18). They demonstrate a clear
genotype–phenotype correlation, with mutations that cause
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more rapid polymerization of the protein causing earlier onset
disease (18). These inclusions cause disease both by
gain-of-function toxicity and loss of function of an important
protease inhibitor (18). One of the striking features of FENIB
is that the ER inclusions of mutant neuroserpin do not activate
the unfolded protein response (UPR) (8,19,20). Instead, they
appear to trigger NF-kB signalling through release of calcium
from the ER, which has been termed the ‘ER overload response’
(EOR) (19). However, before it can form polymers, the majority
of mutant neuroserpin appears to be degraded predominantly by
the ER-associated degradation (ERAD) pathway, although
autophagy may also contribute to this (20). Many ERAD compo-
nents are regulated as part of the UPR; however, how ERAD can
be regulated in a disorder that does not cause ER stress is
unknown.
We report here a critical role for HMGCoA reductase, the lim-
iting enzyme of the cholesterol biosynthetic pathway, in the
clearance of mutant neuroserpin from the ER. This pathway is
upregulated in cells expressing polymers of neuroserpin.
While the interrelationship between the UPR and sterol metabol-
ism is well recognized, this represents the first description of a
link between sterol metabolism and modulation of the proteo-
toxicity mediated by the EOR.
RESULTS
Generation of a human cell model of FENIB
A human cell model of FENIB was developed by expressing neu-
roserpin under the control of the Tet-On promotor in HeLa cells.
Clonal cell lines were generated that conditionally express either
wild-type neuroserpin (Fig. 1A), the naturally occurring G392E
mutant that forms ordered polymers in association with FENIB
(G392E cells) (Fig. 1B) or a synthetic truncation,D neuroserpin,
lacking the C-terminal 132 amino acids (D cells) that we have
previously used as a positive control for ER stress (19,20)
(Fig. 1C). In each cell line, doxycycline induced the expression
of neuroserpin in a concentration-dependent manner as assessed
by western blot analyses and ELISA (Fig. 1). Treatment with
doxycycline at 2 mg/ml for 48 h was considered optimal, provid-
ing a useful dynamic range of neuroserpin expression. D neuro-
serpin could be detected only by western blot analysis as the
monoclonal antibodies used in the ELISA give little signal for
the truncated protein. The ELISA detected either ‘total neuroser-
pin’ with a pool of monoclonal antibodies [1A10, 10B8, 10G12
(18)] or polymers of G392E neuroserpin with the 7C6 antibody
(18). Cells expressing wild-type neuroserpin stained positively
for neuroserpin within the ER and Golgi apparatus, as is
typical of a secretory protein, whereas G392E neuroserpin
formed inclusion bodies of polymers within the ER that recapitu-
late the features of FENIB (Fig. 2).
The next step in the characterization of our human
cell-inducible model of FENIB was to understand the mechan-
ism of degradation of neuroserpin mutants.
Identification of E3 and E2 ligases involved
in the degradation of mutants of neuroserpin
The E3 ligases Hrd1 and gp78 have been implicated in the deg-
radation of various serpins including Alpha-1-antitrypsin (21)
and neuroserpin (22). We decided to investigate the specific
role of these ligases in the degradation of neuroserpin. By
using a Drosophila melanogaster model of FENIB, we con-
firmed the crucial role of these two E3 ligases in ERAD (Supple-
mentary Material, Fig. S1). Then, we tested the depletion of Hrd1
and gp78 in our cells. Silencing ofHrd1 expression was achieved
by transfection with siRNA. While this did not affect the level of
wild-type neuroserpin as detected by western blot analysis
(Fig. 3A), there was a small but significant increase detected
by ELISA (Fig. 3C). In contrast, a control siRNA to neuroserpin
abolished its expression in all cell lines (Fig. 3A, B, E, G). The
double band of immunoreactive neuroserpin observed intermit-
tently in cells expressing wild-type protein (Fig. 3A) is probably
a degradation product as wild-type neuroserpin can be cleaved
by proteases such as tPA. In cells expressing G392E neuroserpin,
depletion of Hrd1 resulted in a striking increase in the level of
Figure 1.Characterization of HeLa cells that conditionally express neuroserpin.
(A) 10% w/v acrylamide SDS–PAGE and western blot analysis (left) and ELISA
(right) for total neuroserpin to assess the concentration response to doxycycline
of cells that conditionally express wild-type neuroserpin. (B) 10% w/v acryl-
amide SDS–PAGE and western blot analysis (top left) and ELISA (top right)
for total neuroserpin to assess the concentration response to doxycycline of
cells that conditionally express G392E neuroserpin. 7.5% w/v acrylamide
non-denaturing-PAGE and western blot analysis (bottom left) for total neuroser-
pin to assess the formation of polymers. ELISA (bottom right, black histogram)
for polymers of G392E neuroserpin detected with the 7C6 monoclonal antibody.
(C) 10% w/v acrylamide SDS–PAGE and western blot analysis (left) and asso-
ciated densities (right) for total neuroserpin to assess the concentration response
to doxycycline of cells that conditionally express D neuroserpin. The data in
(A)–(C) are from three independent experiments, ∗P , 0.05.
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mutant neuroserpin within the cell, as seen by western blot ana-
lysis (Fig. 3B) and ELISA against total neuroserpin (Fig. 3D).
This reflected an increase in polymerized neuroserpin as
shown both by non-denaturing PAGE (Fig. 3E) and polymer-
specific ELISA (Fig. 3F). A similar, albeit less pronounced, in-
crease in neuroserpin was also observed in cells expressing D
neuroserpin (Fig. 3G).
Knock down of gp78 had no effect on the expression of wild-
type neuroserpin when assessed either by western blot analysis
(Fig. 4A) or ELISA for total neuroserpin (Fig. 4C). In contrast,
depletion of gp78 increased the level of polymers in cells expres-
sing G392E neuroserpin when assessed by ELISA without
affecting the total level of neuroserpin (Fig. 4B and D–F).
Finally, knock down of gp78 markedly increased the level of
truncated D neuroserpin (Fig. 4G).
Hrd1 and gp78 knock down were processed on the same
ELISA plates, allowing a direct comparison. From our data
(western blot analysis and ELISA), we concluded that Hrd1
plays an important role in the degradation of G392E polymeric
neuroserpin, while gp78 is preferentially involved in the
degradation of misfolded D neuroserpin despite a role for both
of them in the degradation of polymerogenic and truncated
neuroserpin.
Figure 2. The G392E mutant of neuroserpin is retained in the ER. Confocal mi-
croscopy of HeLa cells cultured for 48 h in the presence or absence of 2 mg/ml
doxycycline. Wild-type or G392E neuroserpin cells are stained for total or poly-
mers of neuroserpin with the 1A10 or 7C6 antibody, respectively (green). The
ER-resident protein calreticulin is stained red. Merged images (yellow) corres-
pond to areas with overlapping red and green staining, showing co-localization
of neuroserpin and the ER. The nucleus is blue with Hoerscht stain. All images
are shown at the same scale, with the exception of wild-type neuroserpin cells
in the presence of doxycycline, stained for total neuroserpin.
Figure 3. Effect of the knockdown of ubiquitin-E3 ligase Hrd1 on neuroserpin
levels in HeLa cells. HeLa inducible cell lines were treated with 2 mg/ml doxy-
cycline and transfected or not with neuroserpin siRNA as a control of transfec-
tion, Hrd1 siRNA or a mock transfection for 2 days. The silencing of Hrd1 in
wild-type cells does not affect the level of neuroserpin as seen by western blot
analysis and densitometry (hatched histogram) (A) and has only a small effect
when assessed by ELISA against total neuroserpin (C). Mock transfection does
not affect the level of neuroserpin, while siRNA targeting neuroserpin abolishes
its expression. The level of neuroserpin increases when Hrd1 is silenced in cells
expressing G392E neuroserpin, as shown by western blot analysis and associated
densitometries (hatched histogram) (B) or by ELISA against total neuroserpin
(D). Western blot analysis of non-denaturing PAGE (E) and ELISA against poly-
mers of neuroserpin (F) demonstrate that the increase in G392E neuroserpin is
associated with an increase in polymers. The truncated protein D neuroserpin
also accumulates in cells when Hrd1 is silenced, but at a lower level when com-
pared with G392E neuroserpin (G). n ¼ 4 independent repeats for each cell line.
∗P, 0.05; ∗∗P , 0.005.
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The Drosophila melanogaster model also suggested the in-
volvement of the E2 ligase UBE2j1 (Supplementary Material,
Fig. S1). To test this in a mammalian system, we depleted our
cells of UBE2j1, the E2 ubiquitin ligase of Hrd1, and UBE2g2,
the E2 ligase of gp78 (23–25). UBE2j2, an E2 ligase that inter-
acts with the E3 ligase mK3 (26), served as a control. Depletion
of UBE2j1, UBE2j2 or UBE2g2 did not affect the level of
wild-type neuroserpin as assessed by western blot analysis or
ELISA for total neuroserpin (Fig. 5A and C). In contrast, the de-
pletion of UBE2j1 resulted in an increase in neuroserpin poly-
mers in cells expressing G392E neuroserpin as observed by
western blot analysis and by ELISA (Fig. 5B and D). Silencing
of UBE2g2 resulted in an increase in neuroserpin levels
(Fig. 5D). Surprisingly, silencing of UBE2j2 decreased the
levels of neuroserpin polymers as determined either by
western blot analysis or ELISA (Fig. 5B and D). Silencing of
either UBE2j1 or UBE2j2 increased levels of D neuroserpin,
whereas the depletion of UBE2j2 had no effect (Fig. 5E). None
of the siRNA treatments affected cell viability or the level of
ER chaperones (data not shown). To summarize, we observed
the UBE2J1 ligase couple to be involved in the degradation of
well-ordered polymers of neuroserpin, while the UBE2g2/
gp78 ligase complex appears to be responsible for the degrad-
ation of misfolded D neuroserpin.
Since we demonstrated that the UPR is not activated in FENIB
(19), we investigated the activation of alternative pathways that
could lead to the activation of ERAD.
Transcriptional analysis of cells expressing polymers of
neuroserpin reveals upregulation of the cholesterol
biosynthetic pathway
In order to identify signals initiated by the polymerization of neu-
roserpin within the ER, we next used oligonucleotide microar-
rays to perform a transcriptional analysis of cells expressing
wild-type, G392E or D neuroserpin. Treatment of Tet-On cells
with 2 mg/ml of doxycycline increased the level of wild-type
neuroserpin mRNA by 3.75 log-fold, G392E neuroserpin by
3.53 log-fold and D neuroserpin by 5.24-log fold (GEO acces-
sion number: GSE46230, and full analysis on Supplementary
Material, Fig. S2). Gene Set Enrichment analysis (27) was per-
formed on the normalized gene expression values for each cell
line (see Materials and Methods). Fifty-four pathways were
upregulated when wild-type neuroserpin was expressed (Sup-
plementary Material, Table S1), while 70 pathways were upre-
gulated following the expression of G392E neuroserpin
(Supplementary Material, Table S2). No pathways were upregu-
lated with a FDR ≤ 0.25 following expression of Delta neuroser-
pin. Unique pathway analysis of the G392E neuroserpin cell line
revealed the cholesterol biosynthetic pathway to be modulated.
This has previously been linked with the responses to ER dys-
function and to ERAD (28–30). Since most genes of this
pathway were upregulated in cells expressing G392E neuroser-
pin but not in cells expressing the wild-type orD neuroserpin, we
chose to examine this response further (Fig. 6).
To validate the Gene Set Enrichment analysis, RT-qPCR was
performed to assess the expression of four key genes in the chol-
esterol biosynthetic pathway (HMGCoA reductase, HMGCoA
synthase, mevalonate (diphospho) decarboxylase and lanosterol
synthase) in cells prior to and following induction of neuroserpin
expression. HMGCoA reductase, HMGCoA synthase and
mevalonate (diphospho) decarboxylase were upregulated in
cells expressing polymers of G392E neuroserpin (Supplemen-
tary Material, Fig. S3). Only HMGCoA reductase was increased
following the expression of D neuroserpin. In order to test the
physiological relevance of this finding, we next set out to
measure the activation of the cholesterol biosynthetic pathway.
Figure4.Effectof the knockdown of the ubiquitin-E3 ligase gp78 on neuroserpin
in HeLa cells. HeLa inducible cell lines were treated with 2 mg/ml doxycycline
and transfected or not with gp78 siRNA for 2 days. There was no change in the
amount of wild-type neuroserpin when assessed by western blot analysis and
associated densitometry (hatched histogram) (A) or by ELISA against total neu-
roserpin (C). A small increase in G392E neuroserpin was seen when gp78 was
silenced as assessed by western blot analysis and associated densitometry
(hatched histogram) (B), but this increase was not statically different when
assessed by ELISA against total neuroserpin (D). However, there was a statistic-
ally significant increase in G392E neuroserpin polymers when measured by
ELISA (E). Western blot analysis of non-denaturing PAGE also shows a small
increase in polymers when gp78 is silenced (F). Silencing of gp78 in cells expres-
sing D neuroserpin resulted in a dramatic increase in protein accumulation as
shown by western blot analysis and associated densitometry (G). n ¼ 4 inde-
pendent repeats for each cell line. ∗P , 0.05 ; ∗∗P , 0.005.
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Polymers of neuroserpin activate the cholesterol
biosynthetic pathway
The transcriptional upregulation of genes in the cholesterol bio-
synthetic pathway is mediated by the SREBP transcription factor
(31). To investigate how the upregulation of this pathway oc-
curred during the expression of neuroserpin, we generated a re-
porter of SREBP2 signalling by fusing the promoter region of
Cricetulus griseus HMG synthase to the pGL2 luciferase
reporter plasmid (Fig. 7A and B). In the presence of doxycycline,
expression of wild-type neuroserpin did not result in SREBP2
activation (Fig. 7A), while G392E polymers of neuroserpin acti-
vated SREBP2 (Fig. 7B). Simvastatin, a potent inhibitor of
HMGCoA reductase, was used as a positive control for the acti-
vation of SREBP2. Our data indicate that the expression of a
polymerogenic mutant of neuroserpin, which are known to acti-
vate the EOR but not the UPR (19), also initiates SREBP2-
dependent signalling.
Inhibition of sterol synthesis leads to a decrease in
neuroserpin ubiquitination, and to the accumulation of
mutants of neuroserpin in both HeLa cells and primary
neurones
Since we had found that polymers of neuroserpin are able to ac-
tivate the cholesterol biosynthetic pathway, we wished to deter-
mine if the degradation of these polymers was also dependent on
this pathway. Treatment with simvastatin (32) significantly
Figure 6. Whole genome and gene set enrichment analysis of cells expressing
mutants of neuroserpin show an upregulation of the cholesterol pathway when
polymers are expressed. Fold changes representation in the cholesterol biosyn-
thesis pathway of cells expressing wild-type, G392E or D neuroserpin based
on the microarray analysis (GEO number GSE46230) followed by a Gene Set En-
richment analysis (27).
Figure 5. Effect of the knockdown of ubiquitin-E2 ligases on neuroserpin levels
in HeLa cells. HeLa cells were induced with 2 mg/ml doxycycline and transfected
with ubiquitin-E2 ligase (UBE2) siRNA for 2 days. Depletion of UBE2j1,
UBE2j2 or UBE2g2 did not affect the level of wild-type neuroserpin as assessed
by western blot analysis and associated densitometry (hatched histogram) (A)
and by ELISA against total neuroserpin (C). In contrast, the depletion of
UBE2j1 results in an increase in neuroserpin polymers in cells expressing
G392E neuroserpin as observed by western blot analysis and densitometry (B)
and by ELISA (D). Silencing of UBE2g2 resulted in a slight increase in neuroser-
pin levels that was only statically different in ELISA (D). UBE2j2 silencing leads
to a decrease in neuroserpin polymer level in HeLa cells as seen by western blot
analysis (B) and ELISA (D). In cells expressing D neuroserpin silencing both
UBE2j1 and UBE2j2 result in an increase in neuroserpin levels, whereas the de-
pletion of UBE2j2 has no effect (E). n ¼ 4 independent repeats for each cell line.
∗P , 0.05.
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reduced the ubiquitination of the polymerogenic G392E neuro-
serpin. Similar results were found when either gp78 or Hrd1 were
depleted by siRNA (Fig. 8).
To understand the homeostatic function of enhanced sterol
synthesis, we determined the consequences of inhibiting sterol
metabolism in HeLa cells that express wild-type and mutant neu-
roserpin. No effect on neuroserpin levels was detected by
western blot or ELISA when wild-type neuroserpin-expressing
HeLa cells were treated with 2 and 5 mM simvastatin for 48 h
(Fig. 9A). However, treatment with simvastatin resulted in a
concentration-dependent accumulation of polymers in cells
expressing G392E neuroserpin, as detected by western blot ana-
lysis (SDS and non-denaturing PAGE) and ELISA (Fig. 9B).
Treatment with simvastatin also increased the level of D neuro-
serpin protein (Fig. 9C). In contrast, inhibition of squalene epox-
idase by terbinofine, oxidosqualene-lanosterol cyclase by
fumarate (Ro48–8071) and cytochrome P450 3A4 by ketocona-
zole did not alter the level of wild-type, G392E orD neuroserpin
within cells (data not shown).
To determine if the observations made in cell lines held true
for primary tissue, we next examined the relationship between
sterol synthesis and the accumulation of neuroserpin polymers
in primary cultures of mouse cortical neurones. Neurones were
transfected either with wild-type neuroserpin or the G392E
mutant and left untreated or treated with simvastatin for 48 h.
The quantity of intracellular neuroserpin was then assessed by
ELISA. Simvastatin had no effect on the quantity of wild-type
neuroserpin (Fig. 9D), but increased the levels of G392E neuro-
serpin in a concentration-dependent manner (Fig. 9E).
DISCUSSION
Mutants of neuroserpin are retained within the ER of neurones to
cause the inclusion body dementia FENIB. This dementia is
unusual as the ordered structure of neuroserpin polymers pre-
vents an UPR (19). Instead, the accumulation of neuroserpin
leads to an activation of the EOR (20). This provides a model
to evaluate the cellular consequences of the retention of
ordered protein within cells.
After creating a cellular model to investigate FENIB, we iden-
tified the E3 and E2 ligases involved in neuroserpin degradation.
This was performed with the use of a Drosophila model of
FENIB that shown accumulation of G392E neuroserpin when
E3 and E2 orthologues were knocked down. It is interesting to
note that the CG5623 depletion (UBE2j1 and j2) did not show
any accumulation while in HeLa cells UBE2j1 shows a clear
effect. These discrepancies between insects and mammals are
well characterized in the literature, for example p53 is only
implicated in cell death in flies while in mammals it has a role
in the control of both cell death and cell cycle regulation (33).
While a previous study has found the E3 ligases gp78 and hrd1
to be involved in neuroserpin degradation (22), we identified dif-
ferences in the specificity of these proteins. Gp78, and its partner
E2 ligase UBE2g2, target unfolded, truncated forms of neuroser-
pin, while hrd1 and UBE2j1 target ordered polymers of neuro-
serpin for degradation by ERAD. Hrd1 (21,34) and gp78 (35)
have also been well-characterized in the degradation process
of mutant alpha-1-antitrypsin and many other misfolded proteins
(36,37).
Microarray analysis, and subsequent quantitative PCR,
revealed that the expression of ordered polymers was associated
with an activation of the sterol biosynthesis pathway. Previous
studies have shown an interaction between ERAD and choles-
terol biosynthetic pathway (38–40). HMGCoA reductase, the
Figure 7.Polymers of neuroserpin activate the cholesterol biosynthesis pathway
in HeLa cells. HeLa cells expressing wild-type (A) or G392E (B) neuroserpin
were induced with 2 mg/ml doxycycline or 5 mM simvastatin for 48 h before col-
lection. SREBP2 activation is indicated by the Luciferase activity of a SREBP
reporter plasmid measured relative to a Renilla luciferase control plasmid. Histo-
grams represent the mean of n ¼ 5. ∗∗P, 0.005.
Figure 8.Degradation of polymers of neuroserpin is dependant of HMGCoA re-
ductase. HeLa cells expressing G392E neuroserpin were induced with 2 mg/ml
doxycycline for 2 days and treated with 40 mM of MG132 for the last 4 h of the
experiment. These cells were treated with or without 5 mM simvastatin or trans-
fected with Hrd1 or gp78 siRNA. Three milligrams of total protein was immuno-
precipitated using a rabbit polyclonal antibody against neuroserpin, and then
assessed by western blot analysis on a 10% w/v acrylamide SDS gel. The mem-
brane was developed using the ubiquitin-P4D1 antibody. Ubiquitination of
G392E neuroserpin was decreased by treatment with simvastatin. A reduction
in ubiquitination was also observed when Hrd1 or gp78 are depleted by siRNA.
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Figure9. Inhibition of the cholesterol biosynthesis pathway leads to an accumulation of mutants of neuroserpin in both HeLa cells and primary neurones. Neuroserpin
expression was induced in HeLa cells (A–C) with 2 mg/ml doxycycline and treated or not with simvastatin (2 or 5 mM) for 2 days. Cell lysates were resolved by 10% w/
v acrylamide SDS- and 7.5% w/v acrylamide non-denaturing PAGE (for G392E neuroserpin) with associated-densitometries (hatched histograms) and measured by
ELISA directed against total neuroserpin (grey histograms). The same membranes were stripped and re-probed to detect actin as a loading control. (A) The expression
of wild-type neuroserpin was unaffected when cells were treated with 2 or 5 mM simvastatin for 2 days. Neuroserpin levels were detected by western blot analysis and
densitometry and ELISA. (B) Treatment of HeLa cells expressing G392E neuroserpin with simvastatin results in a concentration-dependent increase in neuroserpin.
This was apparent on western blot analysis of both SDS (and associated densitometries in hatched histogram) and by ELISA (grey histogram) for total neuroserpin.
Non-denaturing PAGE confirmed that the protein was present as polymers. (C) Treatment with simvastatin increases the amount ofD neuroserpin in HeLa cells when
assessed by western blot analysis and associated densitometry, without a concentration response. Primary neurones were transfected with the wild-type (D) or G392E
(E) neuroserpin after 7 days in vitro and treated or not with simvastatin. Forty-eight hours later, the neurones were lysed and assessed for total neuroserpin by ELISA.
Simvastatin has no effect on wild-type neuroserpin (D) but increases the quantity of G392E neuroserpin in a concentration-dependent manner (E). Data are from three
independent experiments for each cell line. ∗P , 0.05.
4622 Human Molecular Genetics, 2013, Vol. 22, No. 22
rate limiting enzyme in cholesterol biosynthesis, can interact
with the E3 ligase gp78 (28) to mediate its sterol-accelerated
degradation. Moreover, in vitro work has demonstrated that
Hrd1 is involved in the dislocation and the degradation of
HMGCoA reductase (41). From our experiments, we believe
that accumulation of mutant neuroserpin leads to the activation
of the cholesterol biosynthetic pathway. However, only inhib-
ition of HMGCoA reductase and not other enzymes on this
pathway increases the retention of mutant neuroserpin;
HMGCoA reductase is the rate limiting enzyme of the
pathway and so it is likely that accumulation of mutant neuroser-
pin increases HMGCoA reductase, and hence upregulates the
whole pathway.
An interaction between the cholesterol biosynthetic pathway
and ERAD has previously been observed in another neurological
disease. In patients with Gaucher’s disease, the level of intracel-
lular cholesterol appears to modify the degradation of glucocer-
ebrosidase by influencing ERAD (29); a reduced level of
cholesterol biosynthesis leading to less glucocerebrosidase
entering the ERAD pathway. Similarly, in the case of neuroser-
pin, we found that inhibition of cholesterol biosynthesis also
reduced degradation of the pathogenic target protein. Important-
ly, however, whereas the activation of ERAD by misfolding glu-
cocerebrosidase may involve ER stress (19), this is absent during
the accumulation of neuroserpin polymers indicating that a
sterol-independent mechanism can mediate this response.
Taken together, these experiments reveal a reciprocal rela-
tionship between cholesterol biosynthesis and the clearance of
mutant neuroserpin. The accumulation of intracellular polymers
of neuroserpin leads to the induction of genes involved in
cholesterol synthesis, while inhibition of sterol biosynthesis
impairs the ubiquitination of mutant neuroserpin and thus
causes its accumulation.
MATERIALS ANDMETHODS
Reagents
Unless stated otherwise, reagents, buffers, culture media and
serum for cell cultures were from Sigma-Aldrich Co (Dorset,
UK). Custom-made rabbit polyclonal anti-neuroserpin antibody
was produced in our laboratory (42,43). Antibodies were pur-
chased as follow: mouse monoclonal anti-actin antibody
(Abcam), a-Ub P4D1 (Santa Cruz Biotechnology), rabbit
a-HRD1 (Abgent), mouse a-KDEL (Enzo life science), goat
polyclonal anti-rabbit IgG (HRP) and rabbit polyclonal anti-
mouse IgG (HRP) antibodies (Sigma-Aldrich Co). siRNA
gene depletions were performed using a pool of four ONTAR-
GETplus oligonucleotides (Dharmacon) and the GADD34-
siRNA as a scramble control. Simvastatin and MG132 were
from Calbiochem; terbinofine, fumarate and ketoconazole
from Sigma.
Construction of neuroserpin expression plasmids
Plasmids expressing human wild-type, G392E and D neuroser-
pin (truncated protein) are described in Ref. (42). These con-
structs were subcloned into the pTRE-Tight vector (Clontech,
Saint-Germain-en-Laye, France) for the generation of the
stable HeLa Tet-On neuroserpin cell lines.
Generationand characterizationof stableTet-OnHeLa cells
lines expressing neuroserpin
The HeLa Tet-On cell line was purchased from Clontech. Stable
HeLa-neuroserpin cell lines were generated as detailed by the
manufacturer and screened for neuroserpin expression by
western blot analysis, ELISA and immunostaining. The cells
were cultured in DMEM supplemented with 10% v/v Tet-free
approved FBS (Clontech), 200 mg/ml Geneticin and 100 mg/
ml Hygromycin B (both selective antibiotics from Invitrogen,
Paisley, UK), at 378C and 5% v/v CO2 in a humidified incubator.
Neuroserpin expression was typically induced for 2 days by
treatment with doxocycline (Clontech). SDS and non-
denaturing PAGE followed by western-blot analysis and im-
munocytochemistry for confocal microscopy were performed
as described previously (43).
Primary culture of neurones and transfection
Neuronal cultures were prepared from Swiss mouse embryos
(embryonic days 15–16) as described in Ref. (44). Cortices
were dissected and dissociated in DMEM, and plated on
24-well plates previously coated with poly-D-lysine (0.1 mg/
ml) (Sigma) and laminin (0.02 mg/ml) (Fisher Scientific).
Cells were cultured in DMEM supplemented with 5% v/v fetal
bovine serum, 5% v/v horse serum (both from Invitrogen) and
2 mM glutamine. Cultures were maintained at 378C in a humidi-
fied 5% v/v CO2 atmosphere. Cytosineb-D-arabinoside (10 mM)
was added after 3 days in vitro (DIV) to inhibit glial proliferation.
At 7DIV, cells were transfected with plasmids expressing wild-
type or G392E neuroserpin (42) using the Lipofectamine 2000
protocol (Invitrogen) with a transfection efficiency of 20%,
as assessed by a GFP transfection control (data not shown).
Treatment with simvastatin was performed the same day and
cells were harvested for assessment by ELISA 2 days after
transfection.
Sandwich ELISA
Unless stated otherwise, all steps were carried out at room tem-
perature in 50 ml per well. Plates (Corning Inc., Costar 3590)
were coated overnight at 48C with antigen-purified rabbit poly-
clonal anti-neuroserpin antibody at 2 mg/ml in PBS. Next, wells
were washed with 0.9% w/v NaCl, 0.05% v/v Tween20 and
blocked for 2 h with 300 ml/well of blocking buffer (PBS,
0.25% w/v BSA, 0.05% v/v Tween20, 0.025% w/v Na azide).
Standards (recombinant purified wild-type or polymerized
mutant neuroserpin) and unknown samples (cell lysates pre-
pared as for western-blot analysis or fly extracts) were diluted
in blocking buffer and incubated for 2 h. After washing, the
wells were incubated with either a pool of monoclonal antibodies
(1A10, 10B8 and 10G12, each 333 ng/ml) to detect total neuro-
serpin or with an individual monoclonal antibody (7C6 1 mg/ml)
to detect polymers of neuroserpin, diluted in blocking buffer for
2 h. Bound monoclonal antibodies were detected with rabbit
anti-mouse HRP antibody (1:20000 in blocking buffer without
Na azide) for 1 h. After developing for 10 min with TMB sub-
strate solution (Sigma-Aldrich Co.) and stopping the reaction
with 1 M H2SO4, HRP activity was measured in a plate reader
(Molecular Devices, Thermo-max microplate reader) at 450 nm.
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Western blot analysis
Cells were collected by trypsinization and pelleted at 700 g for
10 min at room temperature. The pellet was lysed in 50–
100 ml of lysis buffer (10 mM Tris, 150 mM NaCl, pH 7.4, 1%
v/v Nonidet P40, 1 mM PMSF, protease inhibitor cocktail) and
cleared by spinning at the highest speed in a bench centrifuge
at 48C for 10 min. The protein concentration was measured by
a Bradford assay (Bio-Rad, Hemel Hempstead, UK). Fifty
micrograms of protein was loaded in each lane and separated
in 10% w/v SDS and 7.5% w/v non-denaturing gels and trans-
ferred on PVDF membrane as described in Ref. (43). Rabbit
polyclonal anti-neuroserpin antibody was used at 1:10000 and
secondary goat polyclonal anti-rabbit IgG (HRP) was used at
1:50000. The bands were visualized as described previously
(43). Membranes were stripped in 0.2 N NaOH for 10 min and
re-probed with a mouse monoclonal anti-actin antibody as a
loading control.
Confocal microscopy
Cells were grown and fixed for confocal microscopy, before
staining for the ER and neuroserpin. To stain ER rabbit a calre-
ticulin antibody was diluted to 1:500 (Thermo Scientific) and
detected with Goat a-rabbit AF555 (Invitrogen) diluted 1:300.
Neuroserpin staining was carried out with either the 1A10 anti-
body (to detect total neuroserpin) at 2.5 mg/ml or the 7C6 anti-
body (to detect neuroserpin polymers) at 3.5 mg/ml. Both
1A10 and 7C6 were detected with Goat a-mouse-AF488 (Invi-
trogen) diluted 1:300. D neuroserpin could not be stained with
these antibodies as previously described (18). DNA was
stained with Hoerscht stain at a 1:1000 dilution (Invitrogen).
RNAi transfection
Cells were transfected using Oligofectamine (Invitrogen) at a
final concentration of 40 nM in an antibiotic-free media. After
5 h, normal media was added to the cells. Cells were harvested
48 h after the transfection.
Immunoprecipitation and ubiquitin western blot analysis
Cells were treated and induced as described previously. To
detect ubiquitin after immunoprecipitaiton, cells were trans-
fected with wild-type ubiquitin (in pcDNA3.1) 48 h before the
experiment. During the last 4 h, cells were treated with
MG132 40 mM to inhibit proteasomal degradation. Cells were
harvested like described previously and lysed in the same lysis
buffer supplemented with 10 mM IAA (Sigma). Cell lysate
samples were pre-cleared with rabbit IgG bound to 45 ml of
50% (v/v) Protein A-Sepharose for 30 min at 48C, and then neu-
roserpin was immunoprecipitated overnight at 48C with specific
antibodies pre-bound to Protein A-Sepharose (45 ml of 50%
(v/v) Protein A-Sepharose plus 1 mg of purified antibody at
48C for 2 h). The following day, immunocomplexes were
washed four times with cold PBS and once with washing
buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.5, 1% (v/v)
Nonidet P-40). Immunocomplex proteins were recovered in
SDS–PAGE loading buffer by heating for 5 min at 908C, sepa-
rated on 4–12% w/v Bis-Tris Nupage gel (Invitrogen) and
detected by western blot analysis using the P4D1 antibody
(Santa Cruz) against ubiquitin.
Microarray and analysis
The Cambridge Genomic Service (http://www.cgs.path.cam.ac.
uk) performed the microarray experiments and analysis. Briefly,
total RNA from HeLa Wt, G392E and D cells was collected
using Trizol (Sigma). RNA amplification was performed using
Ambion Total Prep kit (Ambion, UK) and microarrays were
undertaken using Illumina chips according to the manufacturer’s
protocol. Raw data were pre-processed using R software (http
://www.r-project.org) and the bioconductor (http://www.
bioconductor.org) package lumi (45). Probes were removed
from the data set where the Illumina detection P-value was
greater than 0.01. The data were then transformed using the vari-
ance stabilization transformation algorithm (VST) and normal-
ized using the quantile normalization method. Differentially
expressed genes for each condition (wild-type neuroserpin ‘on’
versus wild-type neuroserpin ‘off’, G392E neuroserpin ‘on’
versus G392E neuroserpin ‘off’ and D neuroserpin ‘on’ versus
D neuroserpin ‘off’’) were identified by fitting linear models
with the bioconductor R package limma (46). To account for mul-
tiple hypotheses testing, P-values were adjusted using the Benja-
mini & Hochberg false discovery rate (FDR) correction. In order
to assess the gene expression profiles at a pathway level, Gene Set
Enrichment analysis (27) was performed on the normalized gene
expression values for each group. Gene Set Enrichment analysis
uses a priori defined gene sets to determine pathway differences
between two phenotypic states. Gene expression data are there-
fore evaluated at the pathway level rather than the single gene.
Gene Set Enrichment analysis first ranks the genes according to
their relative difference in gene expression. The ranked list is
then compared with gene sets (pathways) and an enrichment
score (ES) is calculated for each gene. When a gene is present in
the gene set of interest, the running ES is increased. If the gene is
absent the running ES is decreased. The enrichment statistic is the
maximum deviation of the running ES from zero. Statistical sig-
nificance is assessed by performing a permutation test procedure.
To account for the differences in gene set size, a normalized ES is
calculated. Estimated significance levels are also adjusted for
multiple hypothesis testing. FDR is the estimated probability
that a gene set with a given enrichment statistic represents a false-
positive finding.Atotalof639pathways (gene sets)wereanalysed
from Kyoto Encyclopedia of Genes and Genomes, Reactome and
BioCarta databases (http://www.genome.jp/kegg/pathway.html,
http://www.reactome.org/ and http://www.biocarta.com/genes/
index.asp, respectively). Gene sets containing less than 15 and
greater than 500 genes were filtered out, along with gene sets con-
taining no genes from the input data set.
Luciferase assay
To measure SREBP2 activity in HeLa cells, a luciferase reporter
plasmid was created using a design described previously (47).
The promoter region of Cricetulus griseus HMG synthase
from2368 to+1 bp, containing SREBP binding sites, was con-
structed by Eurofins (Germany) with SmaI and XhoI restriction
sites. This region was cloned into the luciferase reporter pGL2
basic vector (Promega, UK). Cells were transfected with 1 mg
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of pGL2–HMG synthase and 50 ng of the control plasmid
pRL-TK (Promega) 72 h before collection. Treatment with
either 2 mg/ml doxycycline or 5 mM simvastatin was adminis-
tered 48 h before collection. Measurement of pGL2-HMG
synthase relative to pRL-TK was carried out with the Dual–
Luciferase Reporter Assay System (Promega).
Statistical analysis
All graphics represent mean+ SEM. Mann–Whitney analysis
was performed in all our experiments unless otherwise men-
tioned. ∗P, 0.05 and ∗∗P , 0.01.
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